SGHTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Sight Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$8.26−0.02 (-0.24%)
Close on Oct 19, 2026
- Market cap
- $450.22M
- P/E (TTM)
- –
- Dividend yield
- –
Sight Sciences, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Interventional Glaucoma | $75.72M | $75.90M | $74.31M | $65.59M | $46.50M | $26.00M | 97.9% | -0.2% |
| Interventional Dry Eye | $1.64M | $3.96M | $6.75M | $5.74M | $2.46M | $1.64M | 2.1% | -58.7% |
By product or service
By region
From the segment and revenue-disaggregation notes of Sight Sciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.